Last reviewed · How we verify
inert tablet
An inert tablet contains no active pharmaceutical ingredient and produces no pharmacological effect.
An inert tablet contains no active pharmaceutical ingredient and produces no pharmacological effect. Used for Clinical trial control arm, Placebo comparator in randomized controlled trials.
At a glance
| Generic name | inert tablet |
|---|---|
| Also known as | oral placebo, sugar pill |
| Sponsor | CMC Ambroise Paré |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Inert tablets are formulated with inactive excipients (such as lactose, cellulose, or starch) and serve as placebos in clinical trials or as control comparators. They are designed to be indistinguishable in appearance from active formulations while delivering no therapeutic or biological activity.
Approved indications
- Clinical trial control arm
- Placebo comparator in randomized controlled trials
Common side effects
- Placebo effect (perceived symptom improvement)
Key clinical trials
- Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder (PHASE2)
- SGLT2i, Pioglitazone, and Ketone Production in T2D (PHASE1)
- Plant Protein With Ashwagandha-Rhodiola for Sleep Quality (NA)
- Examining a Novel Gastrointestinal Intervention to Negate Environmental Toxicants (ENGINE) (PHASE1, PHASE2)
- Nicotinic Acid for the Treatment of Alzheimer's Disease (PHASE1, PHASE2)
- Safety and Impact of Baricitinib on Cell Surivival Pathways, HIV-1 Reservoir and Inflamation in People With HIV-1 (PHASE2)
- Vibegron for ENergy Thinking and Resilience in Aging (PHASE3)
- Applying a Person-Centered Approach to Enhance Cognitive Training in Senior Living Community Residents With Mild Cognitive Impairment (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- inert tablet CI brief — competitive landscape report
- inert tablet updates RSS · CI watch RSS
- CMC Ambroise Paré portfolio CI